Inventiva Sa EBIT per Share

What does Inventiva Sa do? Inventiva Sa is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. Inventiva Sa is listed on the stock market with the ticker IVA and ISIN US46124U1079. It went public through an IPO on July 10, 2020. The company has 77 employees and operates within the Health Care sector. Its primary product development includes Lanifibranor, a peroxisome proliferator-activated receptor agonist currently in the NATiV3 Phase 3 clinical trial for treating adult patients with MASH. Additionally, the company is developing Odiparcil for mucopolysaccharidoses and has a pre-clinical program targeting TGF-ß for idiopathic pulmonary fibrosis. Inventiva Sa's website is https://inventivapharma.com. The company operates internationally, with its headquarters located in Daix, France. It is incorporated under French law, though the founding year is not specified in the provided information. The company's research and development efforts are centered on innovative therapeutic approaches for serious medical conditions. Inventiva Sa is one of the most popular companies on Eulerpool.